Arcus Biosciences Inc

Compare

518 Followers

RCUS Stock Chart & Stats

$20.29

-$0.04(-0.26%)

At close: Jan 08 4:00 PM EST

$20.29

-$0.04(-0.26%)

Day’s Range― - ―

52-Week Range$6.50 - $22.11

Previous CloseN/A

Volume107.84K

Average Volume (3M)1.22M

Market Cap

$2.19B

Enterprise ValueN/A

Total Cash (Recent Filing)$831.00M

Total Debt (Recent Filing)$98.00M

Price to Earnings (P/E)―

Beta2.04

Next Earnings

Feb 25, 2026

EPS Estimate

-1.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding106,430,980

10 Day Avg. Volume1,419,632

30 Day Avg. Volume1,218,769

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)2.77

Price to Sales (P/S)5.20

P/FCF Ratio-7.62

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$31.50

Price Target Upside55.25% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Drug EfficacyCasdatifan monotherapy has demonstrated a longer median progression-free survival of approximately 12.2 months compared to belzutifan, suggesting a potential for longer median PFS with cas + cabo.

Early Treatment BenefitsThe LITESPARK-022 trial shows positive potential for HIF2α inhibitors to be used in early treatment of RCC, indicating benefit across the treatment paradigm.

Pipeline ExpansionThe unveiling of five early-stage programs in autoimmune and inflammatory diseases indicates a strong pipeline and future growth potential.

Bears Say

Arcus Biosciences News

Arcus Biosciences TBA Spot Secondary; price range $18.25-$18.75

Leerink and Goldman Sachs are acting as joint book running managers for the offering. Published first on TheFly...

5h ago

RCUS

Arcus Biosciences announces common stock offering, no amount given

Arcus Biosciences (RCUS) announced that it has commenced an underwritten public offering of its common stock. All of...

7h ago

RCUS

Arcus Biosciences price target raised to $16 from $14 at Goldman Sachs

Goldman Sachs analyst Salveen Richter raised the firm’s price target on Arcus Biosciences (RCUS) to $16 from $14...

15h ago

RCUS

Arcus Biosciences price target raised to $35 from $33 at Wedbush

Wedbush raised the firm’s price target on Arcus Biosciences (RCUS) to $35 from $33 and keeps an Outperform...

1d ago

RCUS

Arcus Biosciences price target raised to $56 from $54 at Citi

Citi raised the firm’s price target on Arcus Biosciences (RCUS) to $56 from $54 and keeps a Buy...

2d ago

RCUS

Arcus Biosciences price target raised to $28 from $24 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arcus Biosciences (RCUS) to $28 from $24 and keeps a...

2d ago

RCUS

Arcus Biosciences reports Q3 EPS ($1.27), consensus ($1.29)

Reports Q3 revenue $30M, consensus $20.3M. “Data from the ARC-20 study demonstrate that casdatifan has a best-in-class profile,...

2d ago

RCUS

Taiho exercises option to develop, commercialize casdatifan in Japan, Asia

Taiho Pharmaceutical and Arcus Biosciences (RCUS) announced that Taiho exercised its option to develop and, if approved, commercialize...

11d ago

RCUS

Arcus Biosciences price target raised to $54 from $47 at Citi

Citi analyst Yigal Nochomovitz raised the firm’s price target on Arcus Biosciences (RCUS) to $54 from $47 and...

18d ago

RCUS

Arcus announces first OS results from Arm A1 of Phase 2 EDGE-Gastric study

Arcus Biosciences (RCUS) announced the first OS results from Arm A1 of the Phase 2 EDGE-Gastric study in...

18d ago

RCUS

Arcus Biosciences Reports Promising Q3 2025 Results

Arcus Biosciences ( ($RCUS) ) has released its Q3 earnings. Here is a breakdown of the information Arcus...

2d ago

RCUS

Arcus Biosciences Advances Cancer Treatment with AB801 Study

Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is conducting a clinical study...

3d ago

RCUS

Arcus Biosciences Advances Phase 3 Trial for Renal Cell Carcinoma

Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is conducting a Phase 3...

3d ago

RCUS

Arcus Biosciences’ Promising Phase 1 Study on Renal Cell Carcinoma

Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is conducting a Phase 1...

3d ago

RCUS

RCUS FAQ

What was Arcus Biosciences Inc’s price range in the past 12 months?

Arcus Biosciences Inc lowest stock price was $6.50 and its highest was $22.11 in the past 12 months.

What is Arcus Biosciences Inc’s market cap?

Arcus Biosciences Inc’s market cap is $2.19B.

When is Arcus Biosciences Inc’s upcoming earnings report date?

Arcus Biosciences Inc’s upcoming earnings report date is Feb 25, 2026 which is in 117 days.

How were Arcus Biosciences Inc’s earnings last quarter?

Arcus Biosciences Inc released its earnings results on Oct 28, 2025. The company reported -$1.27 earnings per share for the quarter, beating the consensus estimate of -$1.31 by $0.04.

Is Arcus Biosciences Inc overvalued?

According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcus Biosciences Inc pay dividends?

Arcus Biosciences Inc does not currently pay dividends.

What is Arcus Biosciences Inc’s EPS estimate?

Arcus Biosciences Inc’s EPS estimate is -1.17.

How many shares outstanding does Arcus Biosciences Inc have?

Arcus Biosciences Inc has 106,430,980 shares outstanding.

What happened to Arcus Biosciences Inc’s price movement after its last earnings report?

Arcus Biosciences Inc reported an EPS of -$1.27 in its last earnings report, beating expectations of -$1.31. Following the earnings report the stock price went up 2.062%.

Which hedge fund is a major shareholder of Arcus Biosciences Inc?

Currently, no hedge funds are holding shares in RCUS

Arcus Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-68.13%

Trailing 12-Months

Asset Growth

-22.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arcus Biosciences Inc

Arcus Biosciences (RCUS) is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. The company specializes in creating treatments that harness the body's immune system to combat various forms of cancer, particularly through its proprietary drug candidates targeting key pathways in the tumor microenvironment. Arcus is engaged in the research and development of its lead programs, which include both immunotherapy and targeted therapy options, aiming to improve patient outcomes in oncology.

Arcus Biosciences (RCUS) Earnings & Revenues

Historic Earnings Reports

RCUS Stock 12 Month Forecast

Average Price Target

$31.50

▲(55.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","57":"$57","18.75":"$18.75","31.5":"$31.5","44.25":"$44.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,18.75,31.5,44.25,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.48,16.75076923076923,20.021538461538462,23.29230769230769,26.56307692307692,29.833846153846153,33.104615384615386,36.37538461538462,39.646153846153844,42.91692307692307,46.1876923076923,49.458461538461535,52.72923076923077,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.48,14.866153846153846,16.252307692307692,17.638461538461538,19.024615384615384,20.41076923076923,21.79692307692308,23.183076923076925,24.56923076923077,25.955384615384617,27.341538461538462,28.72769230769231,30.113846153846154,{"y":31.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.48,13.52,13.56,13.6,13.64,13.68,13.72,13.76,13.8,13.84,13.88,13.92,13.96,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >